

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030778 A1

(51) International Patent Classification⁷: **C07D 491/04**,
A61K 31/438, A61P 25/00

& D Wilmington, 1800 Concord Pike, Wilmington,
Delaware 19850-5437 (US). SMITH, Mark, A [US/US];
AstraZeneca R & D Wilmington, 1800 Concord Pike,
Wilmington, Delaware 19850-5437 (US).

(21) International Application Number:
PCT/GB2004/004116

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; As-
traZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:
24 September 2004 (24.09.2004)

(25) Filing Language: English

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(26) Publication Language: English

(30) Priority Data:
60/505,731 25 September 2003 (25.09.2003) US

(71) Applicant (*for all designated States except MG, US*): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London Greater Lon-
don W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): DORFF, Peter
[US/US]; AstraZeneca R & D Wilmington, 1800 Concord
Pike, Wilmington, Delaware 19850-5437 (US). GOR-
DON, John [US/US]; AstraZeneca R & D Wilmington,
1800 Concord Pike, Wilmington, Delaware 19850-5437
(US). HEYS, John, Richard [US/US]; AstraZeneca R &
D Wilmington, 1800 Concord Pike, Wilmington, Delaware
19850-5437 (US). KEITH, Richard, A [US/US]; As-
traZeneca R & D Wilmington, 1800 Concord Pike,
Wilmington, Delaware 19850-5437 (US). MCCARTHY,
Dennis, J [US/US]; AstraZeneca R & D Wilmington,
1800 Concord Pike, Wilmington, Delaware 19850-5437
(US). PHILLIPS, Eifion [GB/US]; AstraZeneca R

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: LIGANDS



(I)

(57) Abstract: A radioactive compound having the formula (I), where R¹ and Ar are as defined in the specification, pharmaceuti-
cally-acceptable salts thereof, compositions containing such compounds and uses thereof in diagnosis of conditions wherein the α₇
nicotinic receptor is involved.